74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Sangamo Therapeutics Inc
Closed
Sector Healthcare
1.06 -5.36
Overview
Share price change
24h
Min
1.05
Max
1.07
Income | 47M 11M |
|---|---|
Sales | 49M 49M |
EPS | 0.044 |
Profit margin | 21.598 |
Employees | 405 |
EBITDA | 11M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +442.06 upside |
Next Earnings | 12 Mar 2025 |
|---|
Market Cap | 449M 563M |
|---|---|
Previous open | 6.42 |
Previous close | 1.06 |
News Sentiment
By Acuity
50%
50%
157 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Sangamo Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Sangamo Therapeutics Inc Forecast
Price Target
By TipRanks
442.06% upside
12 Months Forecast
Average 5.8 USD 442.06%
High 10 USD
Low 2 USD
Based on 6 Wall Street analysts offering 12 month price targets forSangamo Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
157 / 393 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.
